At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PTPI Petros Pharmaceuticals Inc
Market Closed 12-20 16:00:00 EST
0.2944
-0.0177
-5.67%
盘后0.2600
-0.0344-11.68%
19:59 EST
High0.3200
Low0.2500
Vol1.15M
Open0.3050
D1 Closing0.3121
Amplitude22.43%
Mkt Cap2.95M
Tradable Cap2.77M
Total Shares10.01M
T/O333.13K
T/O Rate12.25%
Tradable Shares9.40M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Maxim Group Keeps Their Buy Rating on Petros Pharmaceuticals (PTPI)
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.